Neoprobe Corp. (OTCBB:NEOP) has received approval for its common stock to be listed on the NYSE Amex.
The Dublin, Ohio-based company expects its stock to begin trading on the exchange “on or around” Feb. 10, according to a statement from Neoprobe.
Neoprobe is currently traded on Nasdaq’s Over-the-Counter Bulletin Board. Company executives have been touting a listing on the NYSE Amex since at least last year.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
“The NYSE Amex listing will provide Neoprobe with improved liquidity and expanded visibility in the investment community, allowing us to strengthen and grow our investor base,” CEO David Bupp said.
Neoprobe is developing a radiopharmaceutical called Lymphoseek, which is a tracing agent that identifies cancerous lymph nodes in patients with breast cancer and melanoma. Cardinal Health will market and distribute the drug.
Neoprobe is expected to file a regulatory application in the next few months that, if approved, would give it the right to begin selling Lymphoseek in the U.S.
The company estimates Lymphoseek’s market at $450 million.
Once a rival to the New York Stock Exchange, the American Stock Exchange was acquired in 2008 by the company that owns its former competitor. Most trading on the NYSE Amex is in small-cap stocks, exchange traded funds and derivatives.